Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Shandong Cancer Hospital and Institute
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07563738CT.gov A 2-part Phase 1/2 Open-label Trial on ODM-212 | — | Recruiting | — | — | — |
NCT06941857CT.gov NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer | — | Recruiting | — | — | — |
NCT06353646CT.gov XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer | — | Recruiting | — | — | — |
NCT05721846CT.gov Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer | — | Active Not Recruiting | — | — | — |
NCT05014776CT.gov Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer | — | Completed | — | — | — |
NCT05116917CT.gov Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer. | — | Terminated | — | — | — |
NCT04117087CT.gov Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer | — | Active Not Recruiting | — | — | — |
NCT04361162CT.gov Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer | — | Active Not Recruiting | — | — | — |
NCT04258150CT.gov Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer | — | Terminated | — | — | — |
NCT03953235CT.gov A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | — | Completed | — | — | — |
Show 5 more trialsShow fewer
NCT03190265CT.gov Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer | — | Completed | — | — | — |
NCT03104439CT.gov Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer | — | Active Not Recruiting | — | — | — |
NCT03098160CT.gov Immunotherapy Study of Evofosfamide in Combination With Ipilimumab | — | Unknown | — | — | — |
NCT00836407CT.gov Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer | — | Completed | — | — | — |
NCT00112580CT.gov MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancreatic Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ipilimumab (this asset) | Shandong Cancer Hospital and Institute | P2 | B · 57 |
| Tinzaparin | Helsinki University Central Hospital | P4 | BBB |
| Oxaliplatin | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Taiho Oncology, Inc. | P3 | BB |
| Fluorouracilum | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Capecitabine | Tianjin Medical University Cancer Institute and Hospital | P3 | BB |
| Irinotecan | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Triglycerides,Medium Chain | Wei Zhou | P4 | BB |
| Desflurane | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | P4 | BB |
+42 more in the Pancreatic Neoplasm cohort
Other indications for Ipilimumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Neoplasm | — | P3 | BB · 71 |
| Melanoma | — | P4 | BB · 69 |
| Cutaneous Melanoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ipilimumab in Pancreatic Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ipilimumab-pancreatic-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →